Literature DB >> 2764527

Pharmacokinetics of subcutaneous azidothymidine in rhesus monkeys.

F M Balis1, C McCully, L Gough, P A Pizzo, D G Poplack.   

Abstract

The pharmacokinetics of subcutaneous bolus and continuous infusion azidothymidine (AZT) was studied in rhesus monkeys. Three animals received 100 mg/m2 as a bolus injection both intravenously and subcutaneously, with the order of administration randomly determined. Two animals received a continuous subcutaneous infusion of 25 mg/m2 per h for 12 or 24 h. AZT was measured in plasma by a reverse-phase high-pressure liquid chromatographic assay. Following intravenous bolus administration, AZT elimination was rapid, with a mean half-life of 1.2 h and a mean clearance of 318 ml/min per m2 (range, 200 to 441 ml/min per m2). The bolus subcutaneous dose was rapidly (time to peak concentration, 15 to 30 min) and nearly completely (fraction absorbed, 92%) absorbed without evidence of local tissue toxicity. With continuous subcutaneous infusion of AZT, the steady state was attained within 4 h and steady-state concentrations in plasma in the two animals exceeded 3.0 mumol/liter. No local tissue toxicity was observed at the infusion site. The subcutaneous route may be a practical alternative to intravenous administration of AZT and deserves further clinical study.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764527      PMCID: PMC284235          DOI: 10.1128/AAC.33.6.810

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Use of the subcutaneous route for the administration of narcotics in patients with cancer pain.

Authors:  E Bruera; C Brenneis; M Michaud; R Bacovsky; S Chadwick; A Emeno; N MacDonald
Journal:  Cancer       Date:  1988-07-15       Impact factor: 6.860

2.  Pharmacokinetics of subcutaneous methotrexate.

Authors:  F M Balis; J Mirro; G H Reaman; W E Evans; C McCully; K M Doherty; R F Murphy; S Jeffries; D G Poplack
Journal:  J Clin Oncol       Date:  1988-12       Impact factor: 44.544

3.  Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.

Authors:  M A Hussain; N Green; D M Flynn; S Hussein; A V Hoffbrand
Journal:  Lancet       Date:  1976-12-11       Impact factor: 79.321

4.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

5.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

6.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

7.  Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection.

Authors:  P A Pizzo; J Eddy; J Falloon; F M Balis; R F Murphy; H Moss; P Wolters; P Brouwers; P Jarosinski; M Rubin
Journal:  N Engl J Med       Date:  1988-10-06       Impact factor: 91.245

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  The pharmacokinetics of zidovudine administered by continuous infusion in children.

Authors:  F M Balis; P A Pizzo; R F Murphy; J Eddy; P F Jarosinski; J Falloon; S Broder; D G Poplack
Journal:  Ann Intern Med       Date:  1989-02-15       Impact factor: 25.391

  9 in total
  2 in total

1.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.

Authors:  R F Schinazi; F D Boudinot; K J Doshi; H M McClure
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys.

Authors:  E M Cretton; R F Schinazi; H M McClure; D C Anderson; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.